치료용 혈장교환 시장 : 세계 산업 규모, 점유율, 동향, 기회 및 예측(2018-2028년) - 제품별, 기술별, 적응증별, 최종사용자별, 지역별, 경쟁

Therapeutic Plasma Exchange Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product, By Technology, By Indication, By End User, By Region and Competition

US $ 4,500 ￦ 6,354,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,766,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,296,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

세계의 치료용 혈장교환 시장은 2022년에 7억 6,201만 달러의 평가액에 달하며, 예측 기간 중 견고한 성장이 전망되며 연간 평균 성장률(CAGR)은 6.75%로 예측되고, 2028년에는 11억 1,160만 달러에 달할 전망입니다.

주요 시장 촉진요인

시장 개요
예측 기간	2024-2028년
2022년 시장 규모	7억 6,201만 달러
2028년 시장 규모	11억 1,160만 달러
CAGR 2023-2028년	6.75%
급성장 부문	신경질환
최대 시장	북미

• 1.신경질환, 신장질환, 혈액질환의 높은 유병률: 신장질환, 급성 간부전, 길랑-바레 증후군(GBS) 등 만성질환의 높은 유병률은 전체 치료용 혈장교환 시장의 성장에 기여하고 있습니다. 치료용 혈장교환의 적용이 급증하고 있으며, 다른 치료법과 비교하여 그 효과를 평가하기 위한 집중적인 연구와 임상시험이 진행되고 있습니다. 이러한 요인들은 치료용 혈장교환 시장의 성장을 크게 촉진하고 있습니다.
• 2.치료용 혈장교환 연구개발의 발전: 연속 흐름 원심분리와 같은 고정밀 기술이 특정 혈액 성분을 효과적으로 분리하고, 차세대 아페레시스 장비의 개발을 포함한 기술 발전이 관찰되고 있습니다. 첨단 TPE 시스템은 수동 개입을 최소화하고 시술의 효율성을 향상시켜 다양한 병태에 대한 채택을 촉진합니다.
• 3.치료용 혈장교환의 적용 범위 확대: 광범위한 신경 질환의 치료가 시장 성장의 중요한 촉매제가 되고 있으며, TPE는 급성 염증성 탈수초성 다발성 신경염, 중증 근무력증(MG), 종양 동반 뇌병증과 같은 질환의 1차 치료제로 간주되고 있습니다. 또한 다양한 다른 신경계 질환의 2차 치료제로도 사용되고 있습니다. 이러한 신경 질환의 유병률은 지속적으로 증가하고 있으며, 이는 시장 발전에 기여하고 있습니다.
• 4.바이오 제약사의 원혈장 수요 증가: 다양한 쇠약성 질환, 만성질환 및 생명을 위협하는 질환의 치료를 위해 바이오 제약사에서 공급되는 혈장에 대한 수요가 증가하고 있는 것은 큰 원동력이 되고 있습니다. 혈장 유래 치료법은 광범위한 질병 치료에 중요한 역할을 하고 있으며, 이는 혈장 유래 제품에 대한 수요와 혈장 페레시스 시장의 성장에 기여하고 있습니다.

주요 시장 과제

• 1.혈장제거술의 위험성: 혈장제거술은 인체에서 혈액의 일부를 빼내어 보충액을 정맥으로 주입하는 시술입니다. 일반적으로 안전하다고 여겨지지만 감염, 알레르기 반응, 저혈압, 내출혈, 전해질 불균형 등 관련 위험이 있습니다. 이러한 위험은 혈장제거술의 보급을 제한할 수 있습니다.
• 2.치료용 혈장교환 제제의 높은 비용: 치료용 혈장교환에 필요한 특수 장비(예: 아펠레시스 장비, 일회용 부품 등)의 비용이 이 시술의 높은 비용에 영향을 미칩니다. 품질 관리 프로세스 및 업계 표준을 준수하는 것은 비용을 더욱 증가시키고, TPE 제품의 제한된 생산 규모도 단위당 비용 상승으로 이어집니다.

주요 시장 동향 :

• 1. 끊임없는 발전: 지속적인 기술 발전은 환자 만족도를 높이고 혈액 유래 제품의 처리를 개선합니다. 연속 흐름 원심분리법과 같은 첨단인 방법은 최소한의 혈류만 필요하기 때문에 채혈을 용이하게 하는 데 있으며, 더욱 진보된 방법입니다. 이러한 기술 개발은 시장 개척의 기회를 창출하고 있습니다.
• 2.소아 용도에서 치료용 혈장 시술의 사용: 치료용 혈장교환 요법은 다양한 질병에서 병원성 물질 제거에 있으며, 소아에 대한 적용이 점점 더 많이 연구되고 있습니다. 여기에는 소아 희귀질환 및 자가면역질환의 치료도 포함되며 시장 성장에 기여하고 있습니다.

부문별 인사이트

• 1. 적응증별 인사이트: 신경계 질환은 노인 인구에서 이러한 질환의 발생률과 유병률 증가와 이 분야에 대한 지속적인 연구로 인해 시장을 지배할 것으로 예상됩니다.
• 2.기술별 인사이트: 원심분리 기술은 공여자의 혈장 제거에 널리 채택되어 비용 효율적이고 효율적인 혈장 제거를 제공하기 때문에 치료용 혈장교환 시장에서 큰 점유율을 차지할 것으로 예상됩니다.

지역별 인사이트 :

북미는 세계 치료용 혈장교환 시장을 독점하고 있으며, 높은 자가면역질환 유병률, 잘 구축된 병원 인프라, 생명공학 기업의 강력한 존재감 등이 그 성장에 기여하고 있습니다.

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 치료용 혈장교환 시장의 전망

• 시장 규모·예측
  • 금액별
• 시장 점유율과 예측
  • 제품별(소모품, 디바이스)
  • 기술별(원심분리, 막분리)
  • 적응증별(신경질환, 혈액 질환, 신장 질환, 대사질환, 기타)
  • 최종사용자별(채혈 센터·혈액 성분 프로바이더, 병원·클리닉, 수혈 센터, 기타)
  • 지역별
  • 기업별(2022년)
• 시장 맵

제6장 북미의 치료용 혈장교환 시장 전망

• 시장 규모·예측
  • 금액별
• 시장 점유율과 예측
  • 제품별
  • 기술별
  • 적응증별
  • 최종사용자별
  • 국가별
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 치료용 혈장교환 시장 전망

• 시장 규모·예측
  • 금액별
• 시장 점유율과 예측
  • 제품별
  • 기술별
  • 적응증별
  • 최종사용자별
  • 국가별
• 유럽 : 국가별 분석
  • 독일
  • 영국
  • 이탈리아
  • 프랑스
  • 스페인

제8장 아시아태평양의 치료용 혈장교환 시장 전망

• 시장 규모·예측
  • 금액별
• 시장 점유율과 예측
  • 제품별
  • 기술별
  • 적응증별
  • 최종사용자별
  • 국가별
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 남미의 치료용 혈장교환 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 제품별
  • 기술별
  • 적응증별
  • 최종사용자별
  • 국가별
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카 치료용 혈장교환 시장 전망

• 시장 규모·예측
  • 금액별
• 시장 점유율과 예측
  • 제품별
  • 기술별
  • 적응증별
  • 최종사용자별
  • 국가별
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 개발
• 합병·인수
• 제품 발표

제13장 세계의 치료용 혈장교환 시장 SWOT 분석

제14장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제15장 경쟁 구도

• Asahi Kasei Corporation
• Baxter International Inc
• B. Braun Melsungen AG
• Cerus Corporation
• Fresenius Kabi AG
• Haemonetics Corporation
• Hemacare Corporation
• IncMedica S.p.A.
• Kawasumi Laboratories
• Terumo Corporation

제16장 전략적 제안

제17장 조사회사 소개·면책사항

KSA

영문 목차

영문목차

The Global Therapeutic Plasma Exchange Market reached a valuation of USD 762.01 Million in 2022 and is expected to experience robust growth during the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 6.75% and expected to reach USD 1111.60 Million through 2028.

Therapeutic plasma exchange (TPE), also known as plasmapheresis, is an advanced medical procedure used to separate pathogenic substances from patients' blood and replace them with replacement fluids, such as albumin solution or fresh frozen plasma. These substances include infective autoantibodies, immune complexes, cryoglobulins, and cholesterol-containing lipoproteins. TPE is widely employed in the treatment of various autoimmune conditions, renal disorders, hematological disorders, and more, contributing significantly to market expansion. It also offers the significant benefit of reducing plasma viscosity and is utilized in the management of chronic diseases as a first-line or second-line therapy or as a supportive treatment. During plasma exchange, a substantial portion of plasma containing toxins and other abnormal matter is extracted from the other blood components and replaced with replacement fluid, such as fresh frozen plasma (FFP) or albumin.

Key Market Drivers:

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 762.01 Million
Market Size 2028	USD 1111.60 Million
CAGR 2023-2028	6.75%
Fastest Growing Segment	Neurological Disorders
Largest Market	North America

• 1. High Prevalence of Neurological, Renal, and Hematological Disorders: The high prevalence of chronic diseases, including nephrological disorders, acute liver failure, Guillain-Barre Syndrome (GBS), and others, contributes to the growth of the overall therapeutic plasma exchange market. There has been a surge in the application of therapeutic plasma exchange, accompanied by intensive research and clinical trials to assess its efficacy compared to other treatments. These factors significantly bolster the growth of the therapeutic plasma exchange market.

• 2. Advances in Therapeutic Plasma Exchange Research and Development: High-precision technologies like continuous-flow centrifugation effectively separate specific blood components, and technological advancements, including the development of next-generation apheresis devices, are being observed. Advanced TPE systems minimize manual intervention, enhance procedure efficiency, and promote the adoption of such systems for a wide range of conditions.

• 3. Expanding Variety of Therapeutic Plasma Exchange Applications: The treatment of a wide array of neurological disorders serves as a significant catalyst for market growth. TPE is considered the primary treatment for conditions such as acute inflammatory demyelinating polyradiculoneuropathy, myasthenia gravis (MG), and paraneoplastic encephalopathies. Additionally, it is employed as a secondary treatment for various other neurological conditions. The prevalence of these neurological disorders continues to rise, contributing to market progress.

• 4. Increasing Demand for Source Plasma from Biopharmaceutical Companies: The growing demand for source plasma from biopharmaceutical companies for the treatment of various debilitating, chronic, and life-threatening disorders is a significant driver. Plasma-derived therapies play a crucial role in the treatment of a broad spectrum of diseases, contributing to the demand for plasma-derived products and the growth of the plasmapheresis market.

Key Market Challenges:

• 1. Risk Associated with Plasmapheresis Procedures: Plasmapheresis procedures involve extracting a portion of blood from the human body and administering replacement fluids intravenously. While generally considered safe, there are associated risks, including infection, allergic reactions, hypotension, internal bleeding, electrolyte imbalance, and others. These risks may limit the widespread adoption of plasmapheresis.

• 2. High Cost of Therapeutic Plasma Exchange Products: The cost of specialized equipment required for therapeutic plasma exchange, such as apheresis machines and disposable components, contributes to the high cost of the procedure. Quality control processes and compliance with industry standards further add to the cost. The limited scale of production for TPE products can also lead to higher per-unit costs.

Key Market Trends:

• 1. Continuous Advancement: Ongoing technological advancements enhance patient satisfaction and improve the processing of blood-derived goods. Advanced methods like continuous-flow centrifugation require minimal blood flow, making them more advanced for facilitating blood collection. These technological developments create opportunities within the market.

• 2. Use of Therapeutic Plasma Procedure in Pediatric Applications: Therapeutic plasma exchange treatments are increasingly studied for pediatric applications in the removal of pathogenic materials in various diseases. This includes the treatment of rare pediatric disorders and autoimmune diseases, contributing to market growth.

Segmental Insights:

• 1. Indication Insights: Neurological disorders are expected to dominate the market, driven by the increasing incidence and prevalence of these diseases in the geriatric population and ongoing research in this field.

• 2. Technology Insights: Centrifugation technology is projected to hold a significant share in the Therapeutic Plasma Exchange market, thanks to its widespread adoption in donor apheresis, offering cost-effectiveness and efficient plasma removal.

Regional Insights:

North America dominates the global therapeutic plasma exchange market, with factors such as a high prevalence of autoimmune diseases, a well-established hospital infrastructure, and a strong presence of biotech enterprises contributing to its growth.

Key Market Players

• Asahi Kasei Corporation
• Baxter International Inc
• B. Braun Melsungen AG
• Cerus Corporation
• Fresenius Kabi AG
• Haemonetics Corporation
• Hemacare Corporation
• IncMedica S.p.A.
• Kawasumi Laboratories
• Terumo Corporation

Report Scope:

In this report, the Global Therapeutic Plasma Exchange Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Therapeutic Plasma Exchange Market, By Product:

• Consumables
• Devices

Therapeutic Plasma Exchange Market, By Technology:

• Centrifugation
• Membrane Separation

Therapeutic Plasma Exchange Market, By Indication:

• Neurological Disorders
• Haematology Disorders
• Renal Disorders
• Metabolic Disorders
• Others

Therapeutic Plasma Exchange Market, By End User:

• Blood Collection Centres & Blood Component Providers
• Hospitals & Clinics
• Blood Transfusion Centres
• Others

Therapeutic Plasma Exchange Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Therapeutic Plasma Exchange Market.

Available Customizations:

• Global Therapeutic Plasma Exchange market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Therapeutic Plasma Exchange Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Consumables, Devices)
  • 5.2.2. By Technology (Centrifugation, Membrane Separation)
  • 5.2.3. By Indication (Neurological Disorders, Hematology Disorders, Renal Disorders, Metabolic Disorders, Others)
  • 5.2.4. By End User (Blood Collection Centers & Blood Component Providers, Hospitals & Clinics, Blood Transfusion Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2022)
• 5.3. Market Map

6. North America Therapeutic Plasma Exchange Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Technology
  • 6.2.3. By Indication
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Therapeutic Plasma Exchange Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Indication
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Therapeutic Plasma Exchange Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Indication
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Therapeutic Plasma Exchange Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Indication
      • 6.3.3.2.4. By End User

7. Europe Therapeutic Plasma Exchange Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Technology
  • 7.2.3. By Indication
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Therapeutic Plasma Exchange Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Indication
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Therapeutic Plasma Exchange Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Indication
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Therapeutic Plasma Exchange Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Indication
      • 7.3.3.2.4. By End User
  • 7.3.4. France Therapeutic Plasma Exchange Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Indication
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Therapeutic Plasma Exchange Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Indication
      • 7.3.5.2.4. By End User

8. Asia-Pacific Therapeutic Plasma Exchange Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Technology
  • 8.2.3. By Indication
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Therapeutic Plasma Exchange Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Indication
      • 8.3.1.2.4. By End User
  • 8.3.2. India Therapeutic Plasma Exchange Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Indication
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Therapeutic Plasma Exchange Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Indication
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Therapeutic Plasma Exchange Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Indication
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Therapeutic Plasma Exchange Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Indication
      • 8.3.5.2.4. By End User

9. South America Therapeutic Plasma Exchange Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Technology
  • 9.2.3. By Indication
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Therapeutic Plasma Exchange Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Indication
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Therapeutic Plasma Exchange Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Indication
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Therapeutic Plasma Exchange Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Indication
      • 9.3.3.2.4. By End User

10. Middle East and Africa Therapeutic Plasma Exchange Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Technology
  • 10.2.3. By Indication
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Therapeutic Plasma Exchange Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Indication
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Therapeutic Plasma Exchange Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Indication
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Therapeutic Plasma Exchange Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Indication
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Therapeutic Plasma Exchange Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Service Offerings
• 15.3. Recent Developments
• 15.4. Key Personnel
• 15.5. SWOT Analysis
  • 15.5.1. Asahi Kasei Corporation
  • 15.5.2. Baxter International Inc
  • 15.5.3. B. Braun Melsungen AG
  • 15.5.4. Cerus Corporation
  • 15.5.5. Fresenius Kabi AG
  • 15.5.6. Haemonetics Corporation
  • 15.5.7. Hemacare Corporation
  • 15.5.8. IncMedica S.p.A.
  • 15.5.9. Kawasumi Laboratories
  • 15.5.10. Terumo Corporation

16. Strategic Recommendations

17. About Us & Disclaimer

관련자료